UBS (UBS) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.86%. A quarter ago, it was expected that this bank would post earnings of $0.42 per share when it actually produced earnings of $0.51, delivering a surprise of +21.43%.Over the last four quarters, the company has surpassed co ...

Company Performance - Algoma Steel Group Inc. reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.45, and compared to a loss of $0.05 per share a year ago, indicating a significant decline in performance [1] - Legato Merger, part of the Zacks Steel - Producers industry, posted revenues of $426.19 million for the quarter ended June 2025, slightly surpassing the Zacks Consensus Estimate by 0.15%, but down from $475.44 million year-over-year [2] - The earnings surprise for Algoma Steel was -64.44%, while Legato Merger has surpassed consensus EPS estimates two times over the last four quarters [1][2] Stock Performance - Legato Merger shares have decreased by approximately 37.4% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for Legato Merger for the upcoming quarter is -$0.65 on revenues of $436.28 million, and for the current fiscal year, it is -$1.74 on revenues of $1.69 billion [7] Industry Outlook - The Steel - Producers industry is currently ranked in the bottom 12% of over 250 Zacks industries, indicating a challenging environment for companies within this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment and stock performance [5][6]

Core Viewpoint - First Commonwealth Financial (FCF) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.34 per share, and showing an increase from $0.36 per share a year ago, indicating a positive earnings surprise of +11.76% [1][2] Financial Performance - The company achieved revenues of $130.99 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.09% and up from $120.2 million year-over-year [2] - Over the last four quarters, FCF has exceeded consensus revenue estimates three times [2] Stock Performance and Outlook - FCF shares have declined approximately 3.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $0.38 for the upcoming quarter and $1.45 for the current fiscal year [4][7] Industry Context - The Zacks Industry Rank for Banks - Northeast places it in the top 16% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Chemed reported quarterly earnings of $4.27 per share, missing the Zacks Consensus Estimate of $4.78 per share, and down from $5.47 per share a year ago, indicating a negative earnings surprise of -10.67% [1][2] Financial Performance - The company posted revenues of $618.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.45% and up from $595.88 million year-over-year [3] - Chemed has exceeded consensus revenue estimates three times over the last four quarters [3] Stock Performance - Chemed shares have declined approximately 12% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [4] - The current Zacks Rank for Chemed is 5 (Strong Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $5.69 on revenues of $632.43 million, and for the current fiscal year, it is $23.09 on revenues of $2.56 billion [8] - The trend of estimate revisions for Chemed was unfavorable prior to the earnings release, which may impact future stock performance [7] Industry Context - Chemed operates within the Medical - Outpatient and Home Healthcare industry, which is currently ranked in the top 38% of over 250 Zacks industries [9] - The performance of Chemed's stock may be influenced by the overall outlook of the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Core Viewpoint - Nabors Industries reported a quarterly loss of $2.71 per share, which was worse than the Zacks Consensus Estimate of a loss of $2.05, but an improvement from a loss of $4.29 per share a year ago [1] Financial Performance - The company posted revenues of $832.79 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.18% and showing an increase from $734.8 million in the same quarter last year [2] - Over the last four quarters, Nabors has not surpassed consensus EPS estimates, indicating ongoing challenges in meeting market expectations [2] Stock Performance - Nabors shares have declined approximately 38.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting it is expected to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$2.00 on revenues of $845.35 million, and for the current fiscal year, it is -$3.53 on revenues of $3.27 billion [7] - The trend of estimate revisions for Nabors has been unfavorable leading up to the earnings release, which may impact future stock performance [6] Industry Context - The Oil and Gas - Drilling industry, to which Nabors belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, indicating a challenging environment for companies in this sector [8]

Company Performance - Amedisys reported quarterly earnings of $1.54 per share, exceeding the Zacks Consensus Estimate of $1.39 per share, and up from $1.32 per share a year ago, representing an earnings surprise of +10.79% [1] - The company posted revenues of $621.86 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.00%, compared to year-ago revenues of $591.19 million [2] - Over the last four quarters, Amedisys has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Outlook - Amedisys shares have increased approximately 6.7% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $1.12 on revenues of $614.59 million, and for the current fiscal year, it is $4.90 on revenues of $2.45 billion [7] - The estimate revisions trend for Amedisys was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Amedisys belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Kadant reported quarterly earnings of $2.31 per share, exceeding the Zacks Consensus Estimate of $1.94 per share, but down from $2.81 per share a year ago [1] - The earnings surprise for the quarter was +19.07%, following a previous surprise of +6.6% when actual earnings were $2.1 per share against an expectation of $1.97 [2] - The company achieved revenues of $255.27 million for the quarter, surpassing the Zacks Consensus Estimate by 3.66%, but down from $274.77 million year-over-year [3] Market Performance - Kadant shares have declined approximately 0.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [4] - The current Zacks Rank for Kadant is 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.64 on revenues of $273.82 million, and for the current fiscal year, it is $9.12 on revenues of $1.03 billion [8] - The outlook for the Manufacturing - General Industrial industry, where Kadant operates, is currently in the top 11% of over 250 Zacks industries, suggesting a favorable environment for performance [9]

Core Insights - O-I Glass reported quarterly earnings of $0.53 per share, exceeding the Zacks Consensus Estimate of $0.41 per share, and showing an increase from $0.44 per share a year ago, resulting in an earnings surprise of +29.27% [1] - The company generated revenues of $1.71 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.52%, and down from $1.73 billion year-over-year [2] - O-I Glass shares have appreciated approximately 32.8% year-to-date, significantly outperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $1.67 billion, while for the current fiscal year, the estimate is $1.40 on revenues of $6.48 billion [7] - The estimate revisions trend for O-I Glass was favorable prior to the earnings release, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Glass Products industry, to which O-I Glass belongs, is currently ranked in the top 1% of over 250 Zacks industries, suggesting a strong performance potential compared to lower-ranked industries [8]

Company Performance - Landstar System (LSTR) reported quarterly earnings of $1.2 per share, exceeding the Zacks Consensus Estimate of $1.16 per share, but down from $1.48 per share a year ago, indicating an earnings surprise of +3.45% [1] - The company posted revenues of $1.21 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.39%, but down from $1.23 billion year-over-year [2] - Over the last four quarters, Landstar has surpassed consensus EPS estimates just once and topped consensus revenue estimates three times [2] Stock Performance - Landstar shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $1.24 billion, and for the current fiscal year, it is $4.86 on revenues of $4.85 billion [7] Industry Outlook - The Transportation - Truck industry, to which Landstar belongs, is currently ranked in the bottom 13% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Landstar's stock performance [5][6]

Company Performance - Penumbra reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and up from $0.64 per share a year ago, representing an earnings surprise of +6.17% [1] - The company posted revenues of $339.46 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.54%, and an increase from $299.4 million year-over-year [2] - Over the last four quarters, Penumbra has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Penumbra shares have declined approximately 3.1% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $341.93 million, and for the current fiscal year, it is $3.72 on $1.35 billion in revenues [7] Industry Context - The Medical - Instruments industry, to which Penumbra belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Penumbra's stock performance [5]